POINT Biopharma Global (PNT) Stock Analysis

What POINT Biopharma Global does

POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors. Beyond these late-stage programs, the company's pipeline includes earlier-stage product candidates such as PNT2001, a next-generation PSMA-targeting agent undergoing preclinical studies for non-metastatic castration-sensitive prostate cancer, and PNT-2004, a program focused on fibroblast activation protein-alpha (FAP-a) with broad potential across multiple tumor types, also in preclinical development. Additionally, POINT Biopharma is actively developing further drug candidates utilizing its CanSEEK technology, which it has sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited. The company was established in 2019 and is headquartered in Indianapolis, Indiana.

Key metrics

ETFs linked to PNT

Broad-market and Healthcare sector ETFs an investor holding POINT Biopharma Global is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PNT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for POINT Biopharma Global?

POINT Biopharma Global trades under the ticker PNT on NASDAQ.

Which exchange is PNT listed on?

PNT is listed on NASDAQ.

What sector does POINT Biopharma Global operate in?

POINT Biopharma Global is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PNT in a portfolio?

PortView shows PNT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.